OPAMM: Oropharyngeal Administration of Mother's Milk in Preterm Infants and Neonatal Infection

Sponsor
Mansoura University Children Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03513146
Collaborator
(none)
200
1
2
31
6.4

Study Details

Study Description

Brief Summary

The protective effect of mother's milk and colostrum on oropharyngeal cavity is not achievable with gavage feeding. This may be increase the risk of colonization of the oropharyngeal cavity with pathogenic bacteria and subsequent increase in the risk of neonatal sepsis. We aim to study the impact of Oropharyngeal Administration of Mother's Milk (OPAMM) before gavage feeding on clinical outcome, bacterial colonization of the GIT of preterm infants with pathogenic bacteria. We also aim to study the immune-protective effect of OPAMM on the incidence of nosocomial sepsis.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Oropharyngeal Administration of Mother's Milk (OPAMM)
N/A

Detailed Description

Preterm, very low Birth Weight (VLBW), infants are at increased risk of feeding intolerance as they have shorter GIT with lower digestive, absorptive and motility capabilities than those of full term infants. Intolerance to enteral feeding has been associated with abdominal distention, initiation of an inflammatory cascade, edema of the bowel, and subsequent development of necrotizing enterocolitis (NEC).

Oral feeding is the best and physiologic method for enteral nutrition of preterm infants. However, because of immaturity of suckling reflex and poor coordination between suckling and swallowing, gavage (oro-gastric or nasogastric tube feeding) has been used as an alternative method of enteral nutrition in preterm infants.

The gut of preterm infants is frequently colonized with pathogenic bacteria due to prematurity, increase gut mucosal permeability, delayed initiation of feeding, formula feeding, and frequent use of antibiotics. This pathogenic bacteria increase the chance of development of nosocomial acquired sepsis and NEC.

Mother's milk, particularly colostrum, is rich in cytokines and other immune agents that provide bacteriostatic, bacteriocidal, antiviral, anti-inflammatory and immunomodulatory protective agents against infection. Thus early gut priming and initiation of enteral feeding of preterm infants with mother's colostrum and milk decrease pathogenic bacterial colonization and subsequent development of sepsis and NEC.

During breast feeding, mother's milk comes in contact with the mouth and oro-pharyngeal pouch which, theoretically, stimulate both oropharyngeal receptors that improves the motility, secretory and absorptive ability of the GIT. Furthermore, anti-inflammatory and pro inflammatory cytokines, which are present abundantly in mother's colostrum and milk, may exert an immuno-protective effect when they come in contact with oropharyngeal as well as GIT mucosa.

We aim to study the impact of Oropharyngeal Administration of Mother's Milk (OPAMM) before gavage feeding on clinical outcome, bacterial colonization of the GIT of preterm infants with pathogenic bacteria. We also aim to study the immune-protective effect of OPAMM on the incidence of nosocomial sepsis.

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Oropharyngeal Administration of mother's milk (OPAMM)Oropharyngeal Administration of mother's milk (OPAMM)
Masking:
Single (Outcomes Assessor)
Masking Description:
Microbiological assessment of bacterial colonization of the oropharyngeal cavity and the GIT will be masked
Primary Purpose:
Prevention
Official Title:
Impact of Oropharyngeal Administration of Mother's Milk Prior to Gavage Feeding on Hospital Acquired Neonatal Infection
Actual Study Start Date :
May 1, 2016
Actual Primary Completion Date :
Dec 1, 2018
Actual Study Completion Date :
Dec 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: OPAMM group

During the pre-feeding period, infants will receive mother's colostrum (to the maximum of 0.2 ml) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 2 to 4 hours. When an infant fits the criteria to start enteral feeding, 0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol. This practice will be continued till the infants reach full oral feeding.

Procedure: Oropharyngeal Administration of Mother's Milk (OPAMM)
0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol

No Intervention: Control Group

During the pre-feeding period, preterm infants will remain NPO. When an infant fits the criteria to start enteral feeding, own mother's colostrum or milk will be given by the regular gavage feeding on intervals regulated by the feeding protocol. This practice will be continued till the infants reach full oral feeding.

Outcome Measures

Primary Outcome Measures

  1. Hospital Acquired late onset neonatal sepsis [Neonatal care unit admission]

    Culture proven neonatal sepsis acquired during neonatal care admission

Secondary Outcome Measures

  1. Colonization of the oro-pharyngeal pouch with pathogenic micro-organism [Neonatal care unit admission]

    Throat swab will be taken at the start of the study and at the end of full enteral feeding.

  2. Colonization of the GIT with pathogenic micro-organism [Neonatal care unit admission]

    Stool culture will be taken at the start of the study and at the end of full enteral feeding.

  3. Necrotizing enterocolitis [Neonatal care unit admission]

    Bell's stage II of necrotizing enterocolitis

  4. Ventilator associated pneumonia [Neonatal care unit admission]

    Clinical and radiological evidence of Ventilator associated pneumonia

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Day to 90 Days
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Preterm infants delivered at less than 32 weeks gestation and less than 1500 grams birth weight will be included in the study
Exclusion Criteria:
  1. Preterm infants < 32 weeks gestation unable to be fed on own mothers' colostrum or milk.

  2. Preterm infants with major congenital anomalies or chromosomal abnormalities.

  3. Preterm infants delivered to mothers with confirmed chorioamnionitis

  4. Preterm infants with confirmed early onset sepsis.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mansoura University Children Hospital Mansourah El Dakahlya Egypt 35111

Sponsors and Collaborators

  • Mansoura University Children Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nehad Nasef, Professor of Pediatrics, Mansoura University Children Hospital
ClinicalTrials.gov Identifier:
NCT03513146
Other Study ID Numbers:
  • MS-15.09.03
First Posted:
May 1, 2018
Last Update Posted:
Jun 16, 2020
Last Verified:
Jun 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 16, 2020